TileDB, Kepler AI, and Tahoe Therapeutics Partner to Transform Single-Cell Data Analysis with AI-Powered Platform

TileDB, Inc., Kepler AI, and Tahoe Therapeutics have announced a partnership to create a platform that allows researchers to run AI agent-based queries on massive single-cell datasets, marking a significant advancement in computational biology. This collaboration integrates TileDB's multimodal database technology, Kepler AI's agent systems, and Tahoe Therapeutics' comprehensive single-cell datasets, resulting in the Tahoe-100M Atlas, a giga-scale single-cell perturbation atlas that is now openly accessible. The platform, which stores over 100 million transcriptomic profiles from 50 cancer cell lines, allows AI agents to work directly with full-resolution single-cell data, providing researchers with real-time analysis capabilities and enabling the discovery of new biomarkers and therapeutic pathways. The platform, available at tahoebio.ai/tahoedive, offers a scalable cloud-native solution to facilitate drug discovery and genomics research, while lowering the barrier for machine learning teams to conduct experiments and train larger models. The collaboration is expected to significantly accelerate research timelines in drug susceptibility, resistance analysis, and genotype-specific transcriptional response characterization.